The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Nurix Therapeutics Inc shares valued at $70,243 were sold by van Houte Hans on May 02 ’25. At $11.33 per share, van Houte Hans sold 6,198 shares. The insider’s holdings dropped to 33,724 shares worth approximately $0.39 million following the completion of this transaction.
Also, JOHANNES VAN HOUTE purchased 6,198 shares, netting a total of over 69,170 in proceeds.
Before that, Hansen Gwenn had sold 3,377 shares from its account. In a trade valued at $38,841, the Chief Scientific Officer traded Nurix Therapeutics Inc shares for $11.50 each. Upon closing the transaction, the insider’s holdings decreased to 3,377 shares, worth approximately $0.71 million.
As published in their initiating research note from Leerink Partners on March 17, 2025, Nurix Therapeutics Inc [NRIX] has been a Market perform and the price target has been revised to $16. Analysts at BTIG Research started covering the stock with ‘”a Buy”‘ outlook in a report released in early December. As of December 06, 2024, BMO Capital Markets has initiated its “an Outperform” rating for NRIX. Earlier on October 24, 2024, UBS initiated its rating. Their recommendation was “a Buy” for NRIX stock.
Analyzing NRIX Stock Performance
On last trading session,, Nurix Therapeutics Inc [NASDAQ: NRIX] rose 2.02% to $11.62. The stock’s lowest price that day was $11.28, but it reached a high of $11.99 in the same session. During the last five days, there has been a drop of approximately -8.00%. Over the course of the year, Nurix Therapeutics Inc shares have dropped approximately -38.32%. Shares of the company reached a 52-week high of $20.66 on 01/27/25 and a 52-week low of $8.18 on 04/10/25.
Support And Resistance Levels for Nurix Therapeutics Inc (NRIX)
According to the 24-hour chart, there is a support level at 11.27, which, if violated, would cause prices to drop to 10.91. In the upper region, resistance lies at 11.99. The next price resistance is at 12.35. RSI (Relative Strength Index) is 52.42 on the 14-day chart, showing neutral technical sentiment.
Is Nurix Therapeutics Inc subject to short interest?
Stocks of Nurix Therapeutics Inc saw a sharp rise in short interest on 2025-05-30 jumping by 0.4 million shares to 14.09 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 13.69 million shares. A jump of 2.83% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 18.91 of the overall float, the days-to-cover ratio (short ratio) jumped to 18.91.
Which companies own the most shares of Nurix Therapeutics Inc (NRIX)?
In terms of Nurix Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 16.5 in the next 12 months, up nearly 44.86% from the previous closing price of $11.39. Analysts anticipate Nurix Therapeutics Inc stock to reach 17 by 2025, with the lowest price target being 16. In spite of this, 16 analysts ranked Nurix Therapeutics Inc stock as Buy at the end of 2025. On October 11, 2024, Jefferies assigned a price target of “a Buy” to the stock and initiated coverage with a $41.
